Combination immunotherapy with vaccine and oncolytic HSV virotherapy is time dependent.
Stacie K TotschAndrew S IshizukaKyung-Don KangSam E GaryAbbey RoccoAaron E FanLi ZhouPablo A ValdésSeung Ho LeeJason LiLuca Peruzzotti-JamettiSarah E BlitzChristopher M GarlissJames M JohnstonJames M MarkertGeoffrey M LynnJoshua D BernstockGregory K FriedmanPublished in: Molecular cancer therapeutics (2024)
These findings substantiate the criticality of combination immunotherapy timing and provide preclinical support for combining SNAPvax with oHSV as a promising treatment approach for both pediatric and adult tumors.